Crinetics Pharmaceuticals, Inc. — Director's Dealing 2018

Jul 18, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2018-07-17

Reporting Person: WIERENGA WENDALL (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	74517	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.73	2025-12-10	Common Stock (25329)		Direct

Footnotes

F1: Includes 15,830 shares of restricted stock issued upon the Reporting Person's early exercise of a stock option that remain unvested and will vest ratably over 20 months following the date of this report, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

F2: The option was initially granted with respect to 60,790 shares. 25% of the shares subject to the option vested on October 30, 2016, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. The shares subject to the option are also subject to accelerated vesting as set forth in the stock option agreement between the Issuer and the Reporting Person. The option was partially exercised with respect to 35,461 shares on April 9, 2018, which shares are included in the total number of shares of common stock owned by the Reporting Person in Table I above.